Illumina said revenue for Q2 2025 was $1.06 billion, down 3% from Q2 2024. The company said its GAAP operating margin was 20.2% and its non-GAAP operating margin was 23.8%.

1. 01

   Illumina said revenue for Q2 2025 was $1.06 billion, down 3% from Q2 2024. The company said its GAAP operating margin was 20.2% and its non-GAAP operating margin was 23.8%.

2. 02

   Illumina said it expects non-GAAP diluted EPS for fiscal 2025 in the range of $4.45 to $4.55. The outlook is up from the $4.20 to $4.30 range set in May. The company said the outlook includes an benefit of approximately 10 cents from recently passed legislation that allows U.S.-based R&D spending to be tax-deductible.

3. 03

   Illumina said operating cash flow for Q2 2025 was $234 million and free cash flow was $204 million. It said cash, cash equivalents and short-term investments at the end of Q2 were $1.16 billion.

4. 04

   Illumina said it repurchased approximately 4.5 million shares in Q2 at an average price of $84.66, for a total of $380 million. The company also said it entered into a definitive agreement to acquire SomaLogic from Standard BioTools and expects the transaction to close in the first half of 2026, subject to regulatory approval.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.